Compare ESPR & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | PRCH |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 753.7M |
| IPO Year | 2013 | 2019 |
| Metric | ESPR | PRCH |
|---|---|---|
| Price | $2.66 | $7.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $7.60 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 5.2M | 976.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.71 | ★ 90.91 |
| EPS | N/A | ★ N/A |
| Revenue | $403,135,000.00 | ★ $482,414,000.00 |
| Revenue This Year | $2.92 | $3.86 |
| Revenue Next Year | N/A | $16.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.31 | 10.18 |
| 52 Week Low | $0.73 | $4.65 |
| 52 Week High | $4.18 | $19.44 |
| Indicator | ESPR | PRCH |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 49.38 |
| Support Level | $2.37 | $6.36 |
| Resistance Level | $3.02 | $8.29 |
| Average True Range (ATR) | 0.18 | 0.43 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 37.62 | 54.98 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.